All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Lymphoma Hub spoke to Stefano Luminari, University of Modena and Reggio Emilia, Modena, IT. We asked, What is the role of treatment line and duration in patients with large B-cell lymphoma (LBCL) treated with chimeric antigen receptor (CAR) T cells?
What is the role of treatment line and duration in patients with LBCL treated with CAR T cells?
First, Luminari highlights the improved outcomes shown with axicabtagene ciloleucel and lisocabtagene maraleucel when compared with standard therapies in the second-line setting, and the clinical implications of these results. He also discusses the impact of the earlier use of CAR T-cell therapy and the importance of identifying patients who have a high risk of relapse who may benefit from timely CAR T-cell therapy. He concludes that CAR T-cell therapy, particularly axicabtagene ciloleucel, represents a major advancement for patients with relapsed LBCL and raises the importance of detecting early signs of relapse.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox